Kimberly Matzel, PA
Internal Medicine · Bluefield, VANPI 1902909872
Payments from drug & device makers
Across 346 payments — averaging $16.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$722
- Boehringer Ingelheim$674
- Amgen$604
- Novo Nordisk$529
- AbbVie$340
- Lilly USA, LLC$266
- plus $2K from 30 others
What the payments were for
- Food & beverage$5,583100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 44 | $722 |
| Boehringer Ingelheim | 52 | $674 |
| Amgen | 41 | $604 |
| Novo Nordisk | 30 | $529 |
| AbbVie | 23 | $340 |
| Lilly USA, LLC | 15 | $266 |
| Novartis | 17 | $255 |
| Shield Therapeutics Inc | 8 | $235 |
| Pfizer | 11 | $208 |
| Scilex Pharmaceuticals Inc. | 9 | $159 |
| Exact Sciences | 8 | $153 |
| Abbott | 15 | $153 |
| Kowa Pharmaceuticals America, Inc. | 9 | $136 |
| Alnylam Pharmaceuticals Inc. | 1 | $109 |
| Astellas Pharma US Inc | 5 | $94 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $90 |
| GSK | 2 | $84 |
| Johnson & Johnson | 5 | $82 |
| Merck | 5 | $76 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $74 |
| Esperion Therapeutics, Inc. | 5 | $68 |
| Currax Pharmaceuticals LLC | 4 | $59 |
| Sunovion Pharmaceuticals Inc. | 5 | $57 |
| Xeris Pharmaceuticals, Inc. | 3 | $55 |
| Mylan Specialty L.p. | 2 | $55 |
| E.r. Squibb & Sons, L.L.C. | 2 | $37 |
| Bayer | 2 | $36 |
| Amarin Pharma, Inc. | 2 | $30 |
| Sumitomo Pharma America, Inc. | 3 | $29 |
| Lundbeck LLC | 1 | $24 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $16 |
| Almatica Pharma LLC | 1 | $16 |
| IBSA Pharma Inc. | 1 | $15 |
| Dexcom, Inc. | 1 | $15 |
| Aimmune Therapeutics, Inc. | 1 | $15 |
| Axsome Therapeutics, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,583 in reported general payments places this provider in the 90th percentile of 2,724 internal medicine providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 172 | $185,591 |
| MounjaroTirzepatide | 157 | $177,060 |
| EliquisApixaban | 181 | $155,319 |
| OzempicSemaglutide | 93 | $117,515 |
| FarxigaDapagliflozin Propanediol | 101 | $105,819 |
| JanuviaSitagliptin Phosphate | 102 | $84,184 |
| MyrbetriqMirabegron | 126 | $73,291 |
| CreonLipase/Protease/Amylase | 28 | $60,432 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 20 | $39,853 |
| XifaxanRifaximin | 11 | $36,646 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 33 | $32,717 |
| Repatha SureclickEvolocumab | 53 | $31,808 |
| XareltoRivaroxaban | 29 | $30,365 |
| Tresiba Flextouch U-200Insulin Degludec | 38 | $26,653 |
| LinzessLinaclotide | 29 | $25,529 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Synjardy, Tradjenta, Synjardy Xr | $674 | $210,719206 claims |
| Lilly USA, LLCMounjaro, Trulicity | $266 | $192,614169 claims |
| PfizerEliquis | $208 | $155,319181 claims |
| AstraZenecaFarxiga, Brilinta, Symbicort | $722 | $117,723125 claims |
| Novo NordiskOzempic | $529 | $117,51593 claims |
| MerckJanuvia, Janumet | $76 | $105,173115 claims |
| AbbVieCreon, Linzess, Viberzi | $340 | $101,70868 claims |
| Astellas Pharma US IncMyrbetriq | $94 | $73,291126 claims |
| GSKTrelegy Ellipta, Arexvy, Breo Ellipta | $84 | $44,49869 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $90 | $36,64611 claims |
| Johnson & JohnsonXarelto | $82 | $30,36529 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $29 | $11,18918 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,724 internal medicine providers in Virginia.
Other internal medicine in Bluefield
- Leroy VaughanRichmond$20.8M
- James ClarkCharlottesville$16.2M
- Nabil AndrawisBurke$8.5M
- Mary BlumbergNorfolk$6.5M
- David RamstadSuffolk$5.8M
- Andrew PoklepovicRichmond$4.6M
- Nashwa GabraBurke$4.3M
- Michael DevittCharlottesville$3.5M
- Richard JacksonRichmond$2.5M
- Sue BrownCharlottesville$2.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.